Share

January 01, 2018; 5 (1) ArticleOpen Access

Disease activity following pregnancy-related discontinuation of natalizumab in MS

Iris Kleerekooper, Zoé L.E. van Kempen, Cyra E. Leurs, Iris Dekker, Theo Rispens, Birgit I. Lissenberg-Witte, Caspar E.P. van Munster, Brigit A. de Jong, Bob W. van Oosten, Bernard M.J. Uitdehaag, Mike P. Wattjes, Joep Killestein
First published December 6, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000424
Full PDF
Citation
Permissions

Comment

Downloads
200

Share

Article Figures & Data

Figures

  • Figure
    Figure Clinical and radiologic disease activity and confirmed disability progression across the 3 groups defined by time to conception

    (A) Relapses refer to the total number of reported relapses; no patient experienced more than 2 relapses. (B) MRI activity refers to active T2 hyperintense and/or contrast-enhanced T1 hyperintense lesions on the first MRI after DMT restart compared with the last MRI before NTZ discontinuation. (C) Confirmed disability progression defined as an increase in the EDSS score of 1.5, 1.0, or 0.5 point at DMT restart compared with the EDSS score of 0, 0.5–5.5, or >5.5 before NTZ discontinuation, respectively. DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; NTZ = natalizumab.

Tables

  • Table 1
  • Table 2

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me